Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cytosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.32 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL1144358 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL76045 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL10496353 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL26123983 | 0.98 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL29123329 | 0.94 | TSHR (0.36) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL5356635 | 0.94 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28199181 | 0.93 | DYRK1A (0.34) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28004771 | 0.90 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL4059 | 0.89 | — | — | |
| Cytosine SCHEMBL1330400 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2154 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703473-A1 | NON-METHYLATED CPG OLIGODEOXYNUCLEOTIDE AND APPLICATION THEREOF | Beijing Ray Medicine Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250391503-A1 | APPLICATION OF GENE MARKERS IN MULTI-CANCER EARLY DETECTION, METHOD FOR CONSTRUCTING EARLY DETECTION MODEL, AND DETECTION DEVICE | GENESEEQ TECHNOLOGY INC. (CA) | 2025-12-25 | — | — | US | claimed |
| EP-4668277-A1 | APPLICATION OF GENE MARKERS IN MULTI-CANCER EARLY DETECTION, METHOD FOR CONSTRUCTING EARLY DETECTION MODEL, AND DETECTION DEVICE | Geneseeq Technology Inc. (CA) | 2025-12-24 | — | — | EP | claimed |
| US-12458688-B2 | Epitopes | SCANCELL LIMITED (GB) | 2025-11-04 | — | — | US | claimed |
| US-12427118-B2 | Injectable cryogel vaccine devices and methods of use thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-09-30 | — | — | US | claimed |
| US-20250207202-A1 | METHODS AND COMPOSITIONS FOR IDENTIFYING HOX GENE SIGNATURES TO ASSIGN SPECIFIC AND EFFECTIVE THERAPIES IN ACUTE MYELOID LEUKEMIA AND OTHER CANCERS | OHIO STATE INNOVATION FOUNDATION | 2025-06-26 | — | — | US | claimed |
| EP-4554628-A1 | HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-21 | — | — | EP | claimed |
| US-12296002-B2 | Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | MEDIGEN VACCINE BIOLOGICS CORPORATION (TW) | 2025-05-13 | — | — | US | claimed |
| WO-2025076398-A1 | IMMUNOMODULATORY NANOPARTICLE CONJUGATESAND USES THEREOF | CORNELL UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| US-20120190631-A1 | MATERIALS AND METHODS RELATING TO GLYCOSYLATION | Iksuda Therapeutics Limited (GB) | 2012-07-26 | — | — | US | claimed |
| US-8173620-B2 | BHQ-caged nucleotide probes photolysable by two-photon excitation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | claimed |
| WO-2010146362-A2 | MATERIALS AND METHODS RELATING TO GLYCOSYLATION | THE UNIVERSITY OF BATH (GB) | 2010-12-23 | — | — | WO | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| US-20090264621-A1 | Lipid-assisted synthesis of polymer compounds and methods for their use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-10-22 | — | — | US | claimed |
| US-6982165-B2 | Nucleic acid sequencing by raman monitoring of molecular deconstruction | INTEL CORPORATION (US) | 2006-01-03 | — | — | US | claimed |
| EP-1366010-A2 | METHOD FOR PRODUCING VINYL, ARYL AND HETEROARYL ACETIC ACIDS AND DERIVATIVES THEREOF | Studiengesellschaft Kohle mbH (DE) | 2003-12-03 | — | — | EP | claimed |
| WO-2002072524-A2 | METHOD FOR PRODUCING VINYL, ARYL AND HETEROARYL ACETIC ACIDS AND DERIVATIVES THEREOF | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2002-09-19 | — | — | WO | claimed |
| EP-0820520-B1 | IMPROVED ENZYMATIC SYNTHESIS OF OLIGOSACCHARIDES | NEOSE TECHNOLOGIES INC (US) | 2002-08-14 | — | — | EP | claimed |
| US-5891452-A | Cosmetic or dermatological composition containing at least one active principle precursor and a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90% | L'OREAL (FR) | 1999-04-06 | — | — | US | claimed |